[The hepatorenal syndrome]

Area of Science:

• Nephrology
• Hepatology
• Internal Medicine

Context:

• Hepatorenal syndrome (HRS) is a severe complication of advanced liver disease, specifically liver cirrhosis with ascites.
• It presents as renal impairment, with two types: Type I (acute, rapid creatinine doubling) and Type II (slower decline in kidney function).
• Current definitive treatment is liver transplantation, but medical management is crucial for patients awaiting transplant or ineligible.

Purpose:

• To outline the characteristics and classifications of hepatorenal syndrome.
• To review current therapeutic strategies based on pathophysiological understanding.
• To highlight the role of aldosteron antagonists, vasopressors, and albumin in managing HRS.

Summary:

• Hepatorenal syndrome (HRS) is defined by the presence of liver cirrhosis, ascites, and renal impairment.
• Type I HRS indicates rapid kidney function decline, while Type II represents a more gradual impairment.
• Management strategies include aldosteron antagonists as a primary therapy, with potential benefits from combining vasopressors and albumin.

Impact:

• Provides a concise overview of hepatorenal syndrome for clinicians and researchers.
• Emphasizes the importance of understanding HRS subtypes for appropriate management.
• Underscores the potential of medical therapies in improving outcomes for patients with HRS.